SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-079104
Filing Date
2023-03-24
Accepted
2023-03-24 16:05:59
Documents
13
Period of Report
2023-03-20
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d487262d8k.htm   iXBRL 8-K 30604
2 EX-3.1 d487262dex31.htm EX-3.1 195158
  Complete submission text file 0001193125-23-079104.txt   393689

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oric-20230320.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20230320_lab.xml EX-101.LAB 19483
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20230320_pre.xml EX-101.PRE 12160
7 EXTRACTED XBRL INSTANCE DOCUMENT d487262d8k_htm.xml XML 3687
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 23759901
SIC: 2834 Pharmaceutical Preparations